Global obesity-drug sales could exceed $130–150B by the mid-2030s, driven by GLP-1/GIP drugs and expanding access beyond the ...

La apuesta de Novo Nordisk por México se afianza con Ozempic y un futuro fármaco oral para obesidad, en un país marcado por ...

Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market leadership. NVO dominates international markets with 72% share and 335% Wegovy ...

The maker of the blockbuster weight loss and diabetes drugs Wegovy and Ozempic have cut the prices for most versions of these medications. Novo Nordisk dropped the price for injectable Wegovy and ...

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs could put it back on the right track. While profit margins may slip due to ...

Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.

Novo Nordisk is set to lay off roughly 9,000 employees across its global workforce of 78,400 as part of a newly launched restructuring initiative. In a Sept. 10 press release, the Danish ...

Medicare has negotiated steep new prices for 15 high-cost drugs, including Novo Nordisk’s blockbuster semaglutide (Wegovy and Ozempic), with negotiated prices set to take effect in 2027. The move cuts ...

Argus downgraded Novo Nordisk (NVO) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking ...

Indian health-tech startup Healthify is in talks to partner with more weight-loss drugmakers to offer health, nutrition and ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

While the Phase III results confirm prior analyst sentiments, a KOL notes that GLP-1RAs could still show potential in the preventive Alzheimer’s setting.